Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
138 studies found for:    "Beta-thalassemia"
Show Display Options
Rank Status Study
21 Active, not recruiting ACE-536 Extension Study - Beta Thalassemia
Condition: Beta-Thalassemia
Intervention: Drug: ACE-536
22 Active, not recruiting Effects of Spirulina on Cardiac Functions in Children With Beta Thalassemia Major
Condition: Beta Thalassemia
Intervention: Other: spirulina
23 Active, not recruiting Study to Evaluate the Effects of ACE-536 in Patients With Beta-thalassemia
Condition: Beta-thalassemia.
Intervention: Drug: ACE-536
24 Terminated Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia
Conditions: Iron Overload;   Beta-Thalassemia
Intervention: Drug: SP-420
25 Completed Phase 1/2 Study of HQK-1001 in Patients With Beta Thalassemia
Condition: Beta Thalassemia
Interventions: Drug: HQK-1001;   Drug: Placebo
26 Recruiting Effect of Spirulina Compared to Amlodipine on Cardiac Iron Overload in Children With Beta Thalassemia
Condition: Beta Thalassemia Major
Interventions: Drug: Spirulina;   Drug: Amlodipine
27 Completed Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions
Condition: Beta-Thalassemia
Interventions: Drug: ICL670;   Drug: deferoxamine
28 Unknown  Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major
Condition: Beta-Thalassemia
Intervention: Drug: deferiprone
29 Completed Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand
Condition: Beta Thalassemia Intermedia
Intervention: Drug: sodium 2,2 dimethylbutyrate
30 Recruiting A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Subjects With Transfusion-Dependent β-Thalassemia
Condition: Beta-Thalassemia
Intervention: Genetic: LentiGlobin BB305 Drug Product
31 Completed Assess the Feasibility and Safety of Granulocyte Colony Stimulating Factor (GCSF) Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major
Conditions: Beta Thalassemia Major;   Congenital Anemias
Intervention: Genetic: GCSF, Central venous line placement, Stem cell Collection (leukapheresis)
32 Withdrawn An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old
Condition: β-thalassemia Major
Intervention: Drug: Deferasirox
33 Active, not recruiting A Study Evaluating the Efficacy and Safety of LentiGlobin BB305 Drug Product in Beta-Thalassemia Major and Sickle Cell Disease
Conditions: Beta-Thalassemia Major;   Sickle Cell Disease
Intervention: Genetic: LentiGlobin BB305 Drug Product
34 Recruiting Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major
Condition: Beta-Thalassemia Major
Interventions: Drug: Basiliximab,;   Drug: cyclosporine A;   Drug: Methotrexate;   Drug: Mycophenolate mofetil
35 Recruiting Benefits of Nigella Sativa in Children With Beta Thalassemia Major
Condition: Nigella Sativa With Beta Thalassemia Major
Intervention: Drug: nigella sativ
36 Completed Efficacy Study of the Use of Sequential DFP-DFO Versus DFP
Conditions: Beta-Thalassemia;   Thalassemia Major
Interventions: Drug: Deferiprone (DFP) and Deferoxamine (DFO);   Drug: Deferiprone (DFP)
37 Completed Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias
Conditions: Beta-thalassemia;   Myelodysplastic Syndromes;   Fanconi Syndrome;   Anemia, Diamond-Blackfan;   Anemia, Aplastic
Intervention: Drug: Deferasirox
38 Unknown  Zoledronic Acid for the Prevention of Bone Loss Post-bone Marrow Transplantation for Thalassemia Major Patients
Conditions: Beta-Thalassemia;   Bone Marrow Transplantation
Interventions: Drug: Zoledronic acid;   Drug: Placebo
39 Unknown  Therapeutic Effects of Silymarin in Patients With B-thalassemia Major
Conditions: Beta-thalassemia Major;   Iron Overload
Interventions: Drug: Silymarin (LEGALON);   Drug: Placebo
40 Active, not recruiting Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.
Conditions: Beta Thalassemia Major;   Beta Thalassemia Intermedia
Interventions: Drug: Sotatercept 0.1mg/kg;   Drug: Sotatercept 0.3mg/kg;   Drug: Sotatercept 0.5mg/kg;   Drug: Sotatercept 0.75mg/kg;   Drug: Sotatercept 1.0mg/kg;   Drug: Sotatercept 1.5mg/kg

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years